"The findings suggest that early detection and management of vitiligo lesions can be improved by estimating the likelihood of its development in transplant recipients."
Patients with acute myeloid leukemia and who have minimal residual disease following hematopoietic cell transplantation have a reduced risk of relapse with gilteritinib maintenance therapy.
The agency called the approval of omidubicel "an important advance" for patients with blood cancer who are undergoing allogeneic umbilical cord blood stem cell transplants.
Despite increased competition from drugs with better clinical profiles and, in some cases, also lower cost, the price tag and rate of prescribing for ibrutinib continues to increase.
Posoleucel, an investigational off-the-shelf T-cell therapy, showed promising safety and efficacy for eradicating multiple viruses in patients who had allogeneic stem cell transplant (allo-SCT).